BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17604501)

  • 1. Ras as a therapeutic target in hematologic malignancies.
    Alvarado Y; Giles FJ
    Expert Opin Emerg Drugs; 2007 May; 12(2):271-84. PubMed ID: 17604501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
    Badar T; Cortes JE; Ravandi F; O'Brien S; Verstovsek S; Garcia-Manero G; Kantarjian H; Borthakur G
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):433-438.e2. PubMed ID: 25795639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
    Crul M; de Klerk GJ; Beijnen JH; Schellens JH
    Anticancer Drugs; 2001 Mar; 12(3):163-84. PubMed ID: 11290863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors.
    Daley GQ
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):11-4. PubMed ID: 12783369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ras signaling pathway proteins as therapeutic targets.
    Adjei AA
    Curr Pharm Des; 2001 Nov; 7(16):1581-94. PubMed ID: 11562300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
    Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the RAS signaling pathway in malignant hematologic diseases.
    Morgan MA; Ganser A; Reuter CW
    Curr Drug Targets; 2007 Feb; 8(2):217-35. PubMed ID: 17305500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesyl transferase inhibitors in myeloid malignancies.
    Lancet JE; Karp JE
    Blood Rev; 2003 Sep; 17(3):123-9. PubMed ID: 12818222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
    Caponigro F
    Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.
    Lancet JE; Karp JE
    Blood; 2003 Dec; 102(12):3880-9. PubMed ID: 12920034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion.
    Clark SS; Zhong L; Filiault D; Perman S; Ren Z; Gould M; Yang X
    Clin Cancer Res; 2003 Oct; 9(12):4494-504. PubMed ID: 14555523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
    Rowinsky EK; Windle JJ; Von Hoff DD
    J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
    Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
    J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
    Karp JE; Lancet JE
    Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agents targeting ras signaling pathway.
    Dancey JE
    Curr Pharm Des; 2002; 8(25):2259-67. PubMed ID: 12369854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function.
    Clark GJ; Drugan JK; Terrell RS; Bradham C; Der CJ; Bell RM; Campbell S
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1577-81. PubMed ID: 8643674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking oncogenic Ras signaling for cancer therapy.
    Adjei AA
    J Natl Cancer Inst; 2001 Jul; 93(14):1062-74. PubMed ID: 11459867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.